JP2022527189A5 - - Google Patents

Info

Publication number
JP2022527189A5
JP2022527189A5 JP2021557924A JP2021557924A JP2022527189A5 JP 2022527189 A5 JP2022527189 A5 JP 2022527189A5 JP 2021557924 A JP2021557924 A JP 2021557924A JP 2021557924 A JP2021557924 A JP 2021557924A JP 2022527189 A5 JP2022527189 A5 JP 2022527189A5
Authority
JP
Japan
Prior art keywords
fgfr3
gene mutations
fgfr
fgfr gene
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021557924A
Other languages
English (en)
Japanese (ja)
Other versions
JP7747521B2 (ja
JP2022527189A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/025166 external-priority patent/WO2020205493A1/en
Publication of JP2022527189A publication Critical patent/JP2022527189A/ja
Publication of JP2022527189A5 publication Critical patent/JP2022527189A5/ja
Priority to JP2025072308A priority Critical patent/JP2025156297A/ja
Application granted granted Critical
Publication of JP7747521B2 publication Critical patent/JP7747521B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021557924A 2019-03-29 2020-03-27 尿路上皮癌の治療のためのｆｇｆｒチロシンキナーゼ阻害剤 Active JP7747521B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025072308A JP2025156297A (ja) 2019-03-29 2025-04-24 尿路上皮癌の治療のためのｆｇｆｒチロシンキナーゼ阻害剤

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP19166428.3 2019-03-29
EP19166428 2019-03-29
EP19188971 2019-07-30
EP19188971.6 2019-07-30
PCT/US2020/025166 WO2020205493A1 (en) 2019-03-29 2020-03-27 Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025072308A Division JP2025156297A (ja) 2019-03-29 2025-04-24 尿路上皮癌の治療のためのｆｇｆｒチロシンキナーゼ阻害剤

Publications (3)

Publication Number Publication Date
JP2022527189A JP2022527189A (ja) 2022-05-31
JP2022527189A5 true JP2022527189A5 (https=) 2023-04-03
JP7747521B2 JP7747521B2 (ja) 2025-10-01

Family

ID=70296138

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021557924A Active JP7747521B2 (ja) 2019-03-29 2020-03-27 尿路上皮癌の治療のためのｆｇｆｒチロシンキナーゼ阻害剤
JP2025072308A Pending JP2025156297A (ja) 2019-03-29 2025-04-24 尿路上皮癌の治療のためのｆｇｆｒチロシンキナーゼ阻害剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025072308A Pending JP2025156297A (ja) 2019-03-29 2025-04-24 尿路上皮癌の治療のためのｆｇｆｒチロシンキナーゼ阻害剤

Country Status (15)

Country Link
US (1) US20220054484A1 (https=)
EP (1) EP3946341A1 (https=)
JP (2) JP7747521B2 (https=)
KR (1) KR20210145211A (https=)
CN (1) CN113645974A (https=)
AU (1) AU2020253827B2 (https=)
BR (1) BR112021019446A2 (https=)
CA (1) CA3130460A1 (https=)
IL (1) IL286729A (https=)
JO (1) JOP20210266A1 (https=)
MA (1) MA55522A (https=)
MX (1) MX2021011926A (https=)
PH (1) PH12021552342A1 (https=)
SG (1) SG11202109902SA (https=)
WO (1) WO2020205493A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4719420A1 (en) * 2023-05-24 2026-04-08 Janssen Pharmaceutica NV Treatment of locally advanced or metastatic urothelial carcinoma with erdafinitib

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
EP0951541B1 (en) 1995-07-31 2005-11-30 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate disease
US6218529B1 (en) 1995-07-31 2001-04-17 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
BRPI0611375A2 (pt) 2005-05-23 2010-08-31 Novartis Ag formas cristalinas e outras de sais de ácido láctico de 4-amino-5-flúor-3-[6-(4-metilpiperazin-1-il)-1h-benzimid azol-2-il]-1h-quinolin-2-ona
US8163923B2 (en) 2007-03-14 2012-04-24 Advenchen Laboratories, Llc Spiro substituted compounds as angiogenesis inhibitors
GB201007286D0 (en) 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
KR102470456B1 (ko) 2014-09-26 2022-11-23 얀센 파마슈티카 엔.브이. Fgfr 억제제를 사용한 치료에 반응할 암 환자를 확인하는 데 있어서 fgfr 돌연변이 유전자 패널의 사용
US10208024B2 (en) * 2015-10-23 2019-02-19 Array Biopharma Inc. 2-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2H)-one compounds as inhibitors of FGFR tyrosine kinases
HUE062453T2 (hu) 2017-02-06 2023-11-28 Janssen Pharmaceutica Nv Rákbetegség kezelése
SG11201906249PA (en) 2017-02-06 2019-08-27 Rainier Therapeutics Inc Methods, compositions, and kits for treatment of cancer
TWI798199B (zh) * 2017-02-06 2023-04-11 比利時商健生藥品公司 癌症治療
JOP20190280A1 (ar) * 2017-06-02 2019-12-02 Janssen Pharmaceutica Nv مثبطات fgfr2 لعلاج سرطان الأوعية الصفراوية

Similar Documents

Publication Publication Date Title
Aapro et al. Adverse event management in patients with advanced cancer receiving oral everolimus: focus on breast cancer
TW201615221A (zh) 炎症用藥臨床新應用
JP2022527482A5 (https=)
JP2020505425A5 (https=)
Abdallah et al. The AMPK modulator metformin as adjunct to methotrexate in patients with rheumatoid arthritis: A proof-of-concept, randomized, double-blind, placebo-controlled trial
CN107308141A (zh) 石斛酚及其组合物在制备预防和治疗动脉粥样硬化药物中的应用
Klein et al. Off‐label use of fumarate therapy for granulomatous and inflammatory skin diseases other than psoriasis vulgaris: a retrospective study
JP2022527189A5 (https=)
JP2023513298A5 (https=)
Sarzi-Puttini et al. Clinical benefits of ibuprofen arginine: a narrative review
JP2022521173A5 (https=)
JPH10167960A (ja) 肝細胞ガン再発抑制剤
Barr et al. Cation metabolism during propofol sedation with and without EDTA in patients with impaired renal function
EP0074426B1 (en) Pharmaceutical oral dosage forms of an active agent capable of forming or releasing bicarbonate ions
CN115645395B (zh) Myls22在制备用于治疗急性肝损伤疾病药物中的应用
Cao et al. Probable rivaroxaban-induced erythema multiforme in children: A case report
CN110179773A (zh) 石斛酚在制备预防和治疗慢性肾小球疾病药物中的应用
WILSON Dialysis and psoriasis
JP2023542296A5 (https=)
AU2024235111B2 (en) 2-hydroxy-octadecene-9-cis-oate for use in the treatment of oncological pathologies and neuropathic pain
Robson et al. Dialysis in scleroderma
US20100041630A1 (en) Methods for Treating or Preventing Inflammation Using a Glycerophosphate Salt
Li et al. ABS1104 EFFICACY AND SAFETY OF TOFACITINIB COMBINED WITH IGURATIMOD IN THE TREATMENT OF RHEUMATOID ARTHRITIS PATIENTS WITH POOR RESPONSE TO csDMARDS: A MULTICENTER, PROSPECTIVE, COHORT STUDY
RU2086256C1 (ru) Способ лечения синдрома раздраженной кишки
RU2370264C2 (ru) Способ детоксикации организма в хирургии местнораспространенного гипернефроидного рака